Everand Logo

Welcome to Everand!

  • STAT

    It’s a big week for debates about drug prices, whether pharma likes it or not

    An insider's guide to the politics and policy of health care.
    by Nicholas Florko and Lev Facher Jun 25, 2019 3 minutes

    D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

    Choose your fighter: The Democratic debates are a chance for candidates to flash their policy chops

    This week’s Democratic primary debates (two 10-candidate panels, each at 9 p.m. on MSNBC this Wednesday and Thursday) are likely to spotlight health care issues ranging from “Medicare for All” to drug pricing to addiction treatment, after months of those issues playing a central role at campaign rallies and town halls.

    Already, Joe Biden to “cure cancer” as president. Sen. Kamala

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks